NCT06914674

Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 14 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Tamoxifen for Solid Pseudopapillary Tumor of the Pancreas

Detailed description

Solid pseudopapillary tumor of the pancreas (SPTP) is a rare neoplasm, predominantly affecting young females, with unclear pathogenesis and hormonal receptor (estrogen/progesterone receptor) expression potentially influencing tumor behavior. While surgical resection is the standard treatment, patients with advanced, metastatic, or recurrent disease lack effective therapies. Case reports suggest tamoxifen, a selective estrogen receptor modulator, may improve outcomes in hormone receptor-positive SPTP. This trial aims to evaluate tamoxifen's efficacy and safety in advanced SPTP.

Conditions

• Pancreatic Neoplasms

Interventions

Type	Name	Description
DRUG	Tamoxifen 20 mg	Tamoxifen: 10 mg orally twice daily. Combination therapy: Chemotherapy, radiotherapy, surgery, or other treatments per NCCN guidelines and patient condition.

Timeline

• Start date: 2025-03-20
• Primary completion: 2027-02-28
• Completion: 2028-02-28
• First posted: 2025-04-06
• Last updated: 2025-04-06

Locations

1 site across 1 country: China